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Abstract
IgE is synthesized locally, in the bronchial mucosa, in both atopic and non-
atopic asthma. The present study of bronchial secretions from asthma patients
confirms that part of this IgE is specific to house dust mite (Dermatophagoïdes
pteronyssinus) allergens, irrespective of atopy. In addition, it reveals that this IgE
response correlates with periostin, but not to eosinophils, in sputum from these
patients, probably in relation to their common IL-4/IL-13 triggering pathway.
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Letter to the Editor
Mite allergen–specific IgE is detectable in
bronchial secretions of patients with non-
atopic asthma and correlates with mucosal
expression of periostin
To the Editor:
Chronic airway inflammation in asthmatic patients is classi-
cally biased toward TH2-type immunity, with IL-4 and IL-13 as
signature cytokines initiating B-cell class-switching to IgE.
Immunoglobulin class-switching classically occurs in the
lymphoid germinal centers, with B cells migrating in the tissue
through the bloodstream. Demonstration of class-switching to-
ward IgE by mucosal resident B cells has been provided in pa-
tients with allergic asthma and rhinitis. It is increasingly
recognized that this local IgE synthesis can occur independently
of systemic IgE sensitization, which is referred to as ‘‘atopy’’ and
evidenced by positive serum IgEmeasurements, skin prick test re-
sponses, or both to at least 1 common aeroallergen. Both the pre-
cise origin of IgE-positive B cells1 and the detailed specificities of
local IgE remain elusive, but studies in allergic rhinitis and
conjunctivitis reported that part of this local IgE might bind to
aeroallergens, such as pollens.2 Our group also reported that func-
tional IgE antibodies to house dust mite (Dermatophagoides pter-
onyssinus) allergens are detected in sputum from patients with
nonatopic asthma.3 Similarly, D pteronyssinus–specific IgE was
reported to be functional in nasal polyp tissues from nonatopic do-
nors.4 The clinical relevance of local specific IgE has been shown
by the demonstration that anti-IgE is effective in nasal polyposis
and asthma independent of atopy.5
In the present study we sought to evaluate sputum IgE
antibodies to D pteronyssinus in a larger series of asthmatic pa-
tients and to correlate this local response to TH2/eosinophilic
inflammation and notably to periostin, which was recently identi-
fied as a surrogate serum marker of airway eosinophilia in asth-
matic patients. We hypothesized that the local production of
allergen-specific IgE antibodies is promoted by IL-13 both in pa-
tients with allergic and those with nonatopic forms of asthma.
Study participants (n5 149), including asthmatic patients and
healthy control subjects, were assessed for the presence ofD pter-
onyssinus–specific IgE in induced sputum. Asthmatic patients
were extensively characterized for lung function, blood and
sputum eosinophil counts, and serum IgE levels (see Table E1
in this article’s Online Repository at www.jacionline.org) and
consented to participate in the study approved by the local ethics
committee (reference 2005/181). Induced sputum was obtained
for each participant by means of inhalation of saline solution
(4.5%; detailed methods for processing are provided in the
Methods section in this article’s Online Repository at www.
jacionline.org). Sputum supernatants were assayed for D ptero-
nyssinus–specific IgE by using ELISA, as previously described.3
Supernatants were also assessed for periostin. The assumption
that periostin could be detected in the sputum is based on the
in vitro observation that human primary bronchoepithelial cells
cultured markedly upregulate periostin gene expression on
IL-13 stimulation.6 We also observed that production of periostin
occurs in air-liquid interface bronchoepithelial cultures in the
basolateral and apical compartments, with the effect of IL-13
being significant only at the apical pole (Fig 2).
It was first confirmed that D pteronyssinus–specific IgE is
detectable in sputum at higher levels in asthmatic patients when
compared with control subjects irrespective of atopy/systemic
IgE sensitization (P < .05 and P < .001, patients with nonatopic
and atopic asthma vs control subjects, respectively; Fig 1, A),
with 76% of patients with allergic asthma being sensitized to D
pteronyssinus (serum D pteronyssinus–specific IgE >0.35 kU/L;
see Table E1). Sputum eosinophil counts were increased in both
patients with atopic and those with nonatopic asthma as either ab-
solute numbers or proportion of leukocytes (P < .001, nonatopic
and atopic asthma vs control subjects), with no difference between
the 2 asthmatic groups (Fig 1, B). Blood and sputum eosinophil
counts were significantly correlated (r 5 0.59, P < .001). Only a
few patients from our series presented with blood eosinophil
counts of 400/mm3 or greater and sputum eosinophil counts of
3% or greater (n5 9 [6.8%]), a profile that was previously associ-
ated with poor control of the disease.7 In sputum, despite levels be-
ing increased only in some asthmatic patients without reaching a
significant between-group difference (Fig 1, C), periostin levels
significantly correlated with D pteronyssinus–specific IgE levels
(r 5 0.37, P < .0001; Fig 1, D) but not eosinophil counts
(r 5 0.06; see Video E1 in this article’s Online Repository at
www.jacionline.org). No significant correlation was found be-
tween sputum periostin and sputum total IgE levels (r 5 0.08,
P5 .43) or other asthma-related parameters. The absence of corre-
lation between periostin levels and sputum eosinophil counts could
be related to the large dispersion of the latter in our study, contrast-
ing with a recent report focused on severe eosinophilic asthma.8
By using immunologic or molecular techniques, several studies
demonstrated that local IgE production occurs in the upper and
lower airways of patients with nonatopic rhinitis, nasal polyposis,
and asthma. In contrast, the specificity of this local IgE was only
recently explored.2-4,9 In the most recent report10 the presence of
local IgE was not confirmed in patients with nonatopic asthma by
using a microarray analysis (ImmunoCAP ISAC; Thermo Scien-
tific, Uppsala, Sweden) of bronchial biopsy homogenates. IgE an-
tibodies to a large panel of allergens, including dust mite
allergens, were not detected in these samples. The discrepancy
between these results and ours could relate to methodological is-
sues. The sensitivity of the microarray could be lower, as sug-
gested by the detection of specific IgE in only a few patients
with allergic asthma (in contrast to positive serum results), prob-
ably because of the described loss of total IgE after extraction and
the assay characteristics, as the authors recognize. Another possi-
bility relates to the site of sampling because it is uncertain
whether tissue-bound IgE levels and secretory (sputum) IgE
levels are correlated and could be affected by different local fac-
tors, including epithelial transport through the low-affinity recep-
tor for IgE (CD23). Thus allergen-specific IgE responses should
be clarified in patients with nonatopic asthma by assessing the
different compartments of the bronchial mucosa, ideally by using
different techniques, to detect the presence of local IgE anti-
bodies. Of note, this study assayed fluid-phase (and not dithio-
threitol-treated4) sputum samples, which could have affected
the results by neglecting cell-bound IgE. In addition, the function-
ality and epitope repertoires should also be investigated and
compared with those in serum because the clinical relevance of
this mucosal response remains in question based on results of
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FIG 1. A, D pteronyssinus–specific IgE antibodies in sputum from patients with nonatopic (n5 34) or atopic
(n 5 77) asthma and sputum from nonatopic control subjects (n 5 14). Lines depict medians and ranges.
B, Sputum eosinophils (percentage of total leukocytes) from patients with nonatopic or atopic asthma
versus nonatopic control subjects. Lines depict medians and ranges. Data were obtained from 39 patients
with intrinsic asthma, 89 patients with atopic asthma, and 21 control subjects. C, Periostin levels as assessed
in DPBS sputum samples in patients with nonatopic (n 5 33) and atopic (n 5 79) asthma versus nonatopic
control subjects (n5 21). Lines depict medians (interquartile ranges). D, Correlation between sputum levels
of periostin and D pteronyssinus-specific IgE. Data were obtained for 114 of 149 subjects (r 5 0.37,
P < .0001), with 35 samples being lower than the detection limit (data not shown) for D pteronyssinus-
specific IgE or periostin (0.75 ng/mL). *P < .05 and ***P < .001.
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FIG 2. Periostin release (during culture for 48 hours) by human airway epithelial cells (AECs) on
recombinant IL-13 stimulation (10 ng/mL every other day) versus control (medium alone) values in the
basolateral and apical compartments, as assessed at weeks 2, 3, and 4 in air-liquid conditions. Data are from
AECs of 14 different donors. Lines depict medians (interquartile ranges). *P < .05.
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in vivo allergen challenge. Thus in contrast to patients with
rhinitis, in whom one group observed clinical responses in
some patients,2 no clinical reactivity was observed on lung chal-
lenge with mite allergen in patients with nonatopic asthma.3
The present data show that periostin can be recovered in
sputum consistently with the apical release of this protein
observed in bronchoepithelial cell cultures at the air-liquid
interface on stimulation by the TH2 cytokine IL-13. Periostin
has been reported to be a novel serum biomarker of bronchial
eosinophilic inflammation, which might be more reliable than
exhaled nitric oxide. The correlation observed in the present study
between sputum levels of periostin and D pteronyssinus–specific
IgE antibodies, but not eosinophil counts, probably relates to their
common triggering mechanism, namely the IL-4/IL-13 cytokine
pathway. A recent study by Bobolea et al8 reports a significant
correlation between sputum periostin levels and eosinophil
counts. This discrepancy with our results might be explained by
the study population, which focused on patients with severe re-
fractory asthma. In any case, the interest in the sputum periostin
level as an additional biomarker of asthma should be considered
in further larger studies, notably to clarify the link between
sputum levels of periostin and eosinophil counts.
Our data confirm that in asthmatic patients local D pteronyssi-
nus–specific IgE antibodies are detectable in sputum irrespective
of atopy and show that this bronchial response correlates to the
local periostin level as a marker of TH2-biased imprinting of the
airway epithelium.
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METHODS
Participants
Asthmatic patients were recruited from outpatient clinics at the Pneu-
mology Department of CHU Liege, Liege, Belgium. Inclusion criteria were a
history of asthma (defined according to the Global Initiative for Asthma
guidelines) since at least 6 months, with documented nonspecific bronchial
hyperreactivity to methacholine, peak expiratory flow variability (>20%
diurnal variability), or both and age of between 18 and 70 years. Patients with
nonatopic asthma were characterized by the absence of a skin prick test
response to a battery of 18 common aeroallergens in our country (cockroach,
D pteronyssinus, Dermatophagoides farinae, cat, dog, tree pollens [birch,
alder, hazel, and ash], grass pollens [5-grass mix], Artemisia species, plan-
tain, Aspergillus species [mix], Cladosporium species, Alternaria species,
Penicillium species, latex, and bird feathers) and by negative (<0.35 kU/L)
serum specific IgE levels (toD pteronyssinus,D farinae, cat, dog, Aspergillus
fumigatus, Alternaria tenuis, and Cladosporium herbarum). Smoking status
was recorded at the time of inclusion. All subjects were stable at the time of
inclusion, with no evidence of respiratory tract infection within the past
6 weeks. All subjects provided written informed consent to participate in
the study, which was approved by our local ethics committee (reference
2005/181). Patients’ and control subjects’ characteristics are depicted in
Table E1.
Sputum sampling and processing
Sputum induction was performed by means of inhalation of either
hypertonic or isotonic saline according to postbronchodilator FEV1 values.
Patients with an FEV1 of greater than 65% of predicted value inhaled 4.5% sa-
line, whereas those with an FEV1 of less than 65% of predicted value were
given 0.9% saline. Saline was inhaled through an ultrasonic nebulizer (Ul-
tra-Neb 2000; DeVilbiss, Somerset, Pa). The cup of the nebulizer was filled
with 50 mL of hypertonic/isotonic saline to which we added 1.75 mL of sal-
butamol solution at 5 mg/mL. FEV1 was measured at 1, 3, 5, and 10 minutes
after the start of the procedure. Inhalation was stopped after 10 minutes or
when a decrease in FEV1 of greater than 20% from baseline had occurred.
Subjects were then asked to rinse their mouths with tap water and to cough
up sputum into a plastic container. For safety reasons, FEV1 was measured
10 and 20 minutes after the end of induction in every patient.
Sputum samples were homogenized with 3:1 (vol/wt) Dulbecco PBS
(DPBS) Ca1- and Mg11-free solution and centrifuged at 800g for 10 minutes
at 48C. Supernatants were stored at 2808C until analysis. The cellular phase
was dispersed in 1 mL of DPBS and diluted twice with Sputolysin reagent
(Calbiochem, San Diego, Calif). The cell suspension was rocked at room tem-
perature for 20 minutes and centrifuged at 400g for 10 minutes at 48C. After
washing with DPBS, the cell pellet was suspended in DPBS for determination
of total cell counts and cell viability by using the trypan blue exclusionmethod
with a manual hemocytometer. The differential cell count was performed on
cytospin preparations stained with Rapi Diff II (Atom Scientific, Manchester,
United Kingdom) by counting 500 nonsquamous cells with a light
microscope.E1
Sputum fluid-phase measurements
D pteronyssinus–specific IgE. The ELISA technique used to detect
IgE in sputum has been extensively detailed.E2 D pteronyssinus–specific anti-
bodies were assayed in PBS supernatants by using ELISA. Microtiter plates
were coated with 5 mg/mL D pteronyssinus extract (Stallergenes, Antony,
France), and 50 mL of undiluted sputum samples was incubated for 1 hour
at 378C. Horseradish peroxidase–conjugated rat monoclonal anti-human IgE
(clone LO-HE17, 11mg/mL) was used as a detection antibody. Extensive con-
trols were used to validate the specificity of our immunoassay by using the
clone LO-HE17.E2
Periostin. Periostin was assayed in sputum supernatants by using Human
Periostin/OSF-2 DuoSet (R&D Systems, Oxon, United Kingdom), according
to themanufacturer’s instructions.Microtiter plates were coatedwith 1mg/mL
of the capture antibody diluted in bicarbonate buffer (pH 9.6) and incubated
overnight at 48C. Plates were then blocked with BSA 1% in PBS for 1 hour at
378C. Standard (12 ng/mL, recombinant periostin) sputum samples (50mL per
well) were then incubated for 1 hour at 378C. Afterward, biotinylated antibody
was added and incubated for 1 hour at 378C. Streptavidin–poly-HRP
(1:10,000, 50 mL per well; BD Biosciences, Erembodegem, Belgium) was
then added. The reaction was developed with TMB (Tetramethylbenzidine,
100 mL per well) and stopped after 15 minutes by H2SO4. Absorbance was
read at 450 nm. Washing of plates was performed 3 times with 0.05%
Tween-20 in PBS between each step. Spiking and recovery assays have
been run on pooled (10 unselected samples) sputum supernatants to validate
the dosing method and reported a mean recovery of 81% of periostin.
Primary bronchoepithelial cell cultures
Primary airway epithelial cells (AECs) were derived from proximal
specimens of lung tissue of 14 patients undergoing lung resection surgery for
a solitary tumor. Lung tissue was sampled away from the tumor site to obtain a
large sample for primary AEC culture. AECs were then cultured in polarized
and air-liquid interface conditions to reconstitute a pseudostratifiedmucociliary
epithelium.E3 Twelve-well polyester membrane inserts (0.4-mm pore size;
Corning, Corning, NY) were coated with 0.2 mg/mL collagen IV (Sigma-Al-
drich, St Louis, Mo), and then AECs were seeded at a density of 50,000 cells
per well. AECs were cultured in submerged conditions until confluence
(approximately 10 days), and cell differentiationwas then allowed by removing
medium in the apical compartment (ie, the air-liquid interface condition) for 15
to 21 days. AECs were cultured in bronchial epithelial cell basal medium/Dul-
becco modified Eagle medium (1:1) medium supplemented with penicillin
(100 U/mL), streptomycin (100 mg/mL), bovine pituitary extract (52 mg/
mL), insulin (5 mg/mL), hydrocortisone (0.5 g/mL), transferrin (10 mg/mL),
epinephrine (0.5 mg/mL), epidermal growth factor (0.5 ng/mL), triiodothyro-
nine (3.25 ng/mL), BSA (1.5 mg/mL), and retinoic acid (30 ng/mL; Lonza,
Verviers, Belgium). IL-13 (R&D Systems, Abingdon, United Kingdom) was
added to basolateral medium (10 ng/mL) every 2 days of air-liquid interface
culture for 2, 3, and 4 weeks. The basolateral medium was renewed every other
day (600mL), and 48 hours before each time point sampling, the apical surface
was washed with PBS to remove most mucus and secreted factors. The day of
collection, the apical surface was sampled with 300 mL of PBS in which peri-
ostin content was assessed (in undiluted samples), thus representing its produc-
tion during 48 hours on resting or IL-13–stimulated conditions. A 2-fold
dilution factor has been applied for basolateral concentrations.
Statistics
The Kruskal-Wallis test with the Dunn posttest was applied to periostin
levels, IgE (both specific or total) sputum levels, and cellular counts, as well as
analysis of AEC-pulsed cultures. Pearson analysis was used for correlation
analysis. A P value of less than .05 was considered significant.
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TABLE E1. Study participants’ characteristics
Patients with intrinsic
asthma (n 5 39)
Patients with atopic
asthma (n 5 89) Control subjects (n 5 21)
Age (y) 54.8 6 15.5* 47.5 6 15.9 55.9 6 9.3
Sex (M/F) 14/25 38/51 5/10
Current smokers or exsmokers 19 35 9
Pack years smoked 24 6 15 17 6 18 15 6 7
ICS therapy 24 (66%) 57 (64%) —
ICS daily dose (BDP eq) 700 (200-1400) 700 (100-1400) —
FEV1 (% predicted) 80 (43-134) 83 (34-117) 106 (62-115)
FEV1/FVC ratio (%) 69.8 (48.3-133.3) 73.5 (41-41) 78 (64-86)
FENO (ppb) 21.6 (4.5-192) 29.7 (7-347.6) NA
Blood eosinophils (%) 2.65 (0.1-15.6) 2.9 (0-13.3) NA
Sputum eosinophils (%) 8.5 (0-88) 9.4 (0.4-76.5) 0.4 (0-1.5)
Serum total IgE (kU/L) 139 (4-999)* 161 (2-3183) NA
Data are presented as medians (ranges), except age and ICS therapy (mean 6 SD).
BDP eq, Beclomethasone dipropionate equivalent; F, female; FENO, fraction of exhaled nitric oxide; FVC, forced vital capacity; ICS, inhaled corticosteroids; M, male; NA, not
applicable.
*P < .05 versus patients with atopic asthma.
P < .01 versus control subjects.
P < .001 versus control subjects.
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